

Dynamic Article Links **>** 

Cite this: DOI: 10.1039/c0xx00000x

## **Supporting Infomation**

www.rsc.org/xxxxxx

10

## **3,4,3-LI(1,2-HOPO):** *In Vitro* Formation of Highly Stable Lanthanide Complexes Translates into Efficacious *In Vivo* Europium Decorporation

Manuel Sturzbecher-Hoehne,<sup>a</sup> Clara Ng Pak Leung,<sup>a</sup> Anthony D'Aléo,<sup>a</sup> Birgitta Kullgren,<sup>a</sup> Anne-Laure Prigent,<sup>a</sup> David K. Shuh,<sup>a</sup> Kenneth N. Raymond<sup>a,b</sup> and Rebecca J. Abergel<sup>\*a</sup>

<sup>a</sup>Chemical Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA. E-mail: rjabergel@lbl.gov; Fax: +1 510 486 5596; Tel: +1 510 486 5249

<sup>b</sup>Department of Chemistry, University of California, Berkeley, CA 94720-1460, USA.



*Figure S1*. Absorption spectra of  $[Ln^{III}(3,4,3-LI(1,2-HOPO))]^{-15}$  complexes in the visible, pH = 7.4, I = 0.1M (KCl).

<sup>20</sup> Table S1. Lanthanide Hydrolysis Constants Included in Stability Constants Refinement.<sup>a</sup>

Species	La	Pr	Nd	Sm	Eu	Gd	Tb	Dy	Но	Er	Tm	Yb	Lu
$MH_{-1}^{b}$	-8.8	-8.3	-8.2	-8.1	-8.1	-8.1	-7.9	-7.9	-7.8	-7.7	-7.7	-7.7	-7.4
$MH_{-2}^{c}$		-15.6	-15.3		-14.4	-14.5		-13.6					
$MH_{-3}^{d}$	-20.3	-22.3	-23.2	-23.9	-24.5	-24.1	-24.3	-23.9	-24.5	-24.7	-24.7	-24.7	-25.1
$M_2H_{-2}^{c}$	-17.1			-14.1						-13.1		-12.7	

<sup>*a*</sup>All values are reported as log  $\beta$  and were previously reported in A. E. Martell, R. M. Smith, R. J. Motekaitis, NIST Critically Selected Stability Constants of Metal Complexes: Version 8.0.

<sup>b</sup>The values for MH<sub>-1</sub> are corrected for I = 0.1 M with the help of the equation used in Klungness, G.D. and Byrne, R.H. <sup>25</sup> *Polyhedron*, 2000, **19**, 99-107.

 $^{\rm c}I = 2.0$  M.

 ${}^{\rm d}I = 0.0$  M.

30

Metal	Species	$m/z^b$
La	[La <sup>III</sup> (3,4,3-LI(1,2-HOPO))] <sup>-</sup>	885
Pr	$[\Pr^{III}(3,4,3-LI(1,2-HOPO))]^{-1}$	887
Nd	[Nd <sup>III</sup> (3,4,3-LI(1,2-HOPO))] <sup>-</sup>	890
Sm	[Sm <sup>III</sup> (3,4,3-LI(1,2-HOPO))] <sup>-</sup>	898
Eu	$[Eu^{III}(3,4,3-LI(1,2-HOPO))]^{-1}$	899
Gd	[Gd <sup>III</sup> (3,4,3-LI(1,2-HOPO))] <sup>-</sup>	904
Tb	$[\text{Tb}^{III}(3,4,3-\text{LI}(1,2-\text{HOPO}))]^{-1}$	905
Dy	[Dy <sup>III</sup> (3,4,3-LI(1,2-HOPO))] <sup>-</sup>	910
Но	[Ho <sup>III</sup> (3,4,3-LI(1,2-HOPO))] <sup>-</sup>	911
Er	[Er <sup>III</sup> (3,4,3-LI(1,2-HOPO))] <sup>-</sup>	914
Tm	[Tm <sup>III</sup> (3,4,3-LI(1,2-HOPO))] <sup>-</sup>	915
Yb	[Yb <sup>III</sup> (3,4,3-LI(1,2-HOPO))] <sup>-</sup>	920
Lu	[Lu <sup>III</sup> (3,4,3-LI(1,2-HOPO))] <sup>-</sup>	921

*Table S2.* Observed Mass-to-Charge Ratios for [Ln<sup>III</sup>(3,4,3-LI(1,2-HOPO))]<sup>-</sup> complexes at pH 7.4.<sup>*a*</sup>

 ${}^{a}$ [3,4,3-LI(1,2-HOPO)] = 0.5 mM [Ln<sup>III</sup>] = 0.05 mM, no buffer added.

<sup>5</sup> <sup>b</sup>Reported numbers correspond to the main peaks in each spectrum.

*Table S3.* Promotion of <sup>152</sup>Eu Excretion in Mice by Injected Octadentate Ligands.<sup>*a*</sup>

Fraction of injected	<sup>152</sup> Eu (%,	mean $\pm$ SD)	at 24 h
	· · · ·		

	Excreta <sup>b</sup>						
Ligand	Liver	Skeleton	Soft tissue	Kidneys	Whole body	Feces	Urine
Control	$30.7 \pm 1.93$	$28.9 \pm 1.25$	$6.29\pm0.90$	$1.0\pm0.22$	$67.0 \pm 1.21$	2.19	30.8
DTPA	$22.0\pm0.90$	$25.9\pm2.17$	$4.94\pm0.27$	$0.78\pm0.09$	$53.7 \pm 1.78$	8.71	37.6
3,4,3-LI(1,2-HOPO)	$1.24\pm0.22$	$12.8\pm0.47$	$3.12\pm0.31$	$0.44\pm0.10$	$17.6\pm0.71$	52.6	29.8
<i>a</i>			152_				

<sup>10</sup> <sup>*a*</sup>Groups of five mice were injected intravenously with <sup>152</sup>Eu; mice were injected intraperitoneally with 30 µmol/kg of a ligand at 1 h; control mice were given 0.14 M NaCl (normal saline) intraperitoneally; mice were euthanized at 24 h. Data, expressed as percent of injected <sup>152</sup>Eu (%, mean  $\pm$  SD), were normalized to 100% material recovery for each five-mouse group. Discrepancies are due to rounding. SD = [ $\Sigma$  dev<sup>2</sup> (n-1)<sup>-1</sup>]<sup>1/2</sup>; for tissues, n = number of mice. <sup>*b*</sup>Excreta of each five-mouse group were pooled; no SD is available.

15

Table S4. In Vivo Stability of Intraperitoneally Injected <sup>152</sup>Eu Complexes.<sup>a</sup>

Fraction of injected $^{152}$ Eu (%, mean ± SD) at 24 h								
	Excreta <sup>b</sup>							
Ligand	Liver	Skeleton	Soft tissue	Kidneys	Whole body	Feces	Urine	
DTPA	$0.09\pm0.02$	$0.07\pm0.05$	$0.22\pm0.11$	$0.11 \pm 0.025$	$0.49\pm0.12$	10.1	89.4	
3,4,3-LI(1,2-HOPO)	$0.05\pm0.03$	$0.02\pm0.03$	$0.10\pm0.04$	$0.022\pm0.004$	$0.20\pm0.07$	89.3	10.5	
<sup>a</sup> Groups of five mice	were injected	intraperitonea	ally with <sup>152</sup> Fi	1-ligand comple	exes: 5 umol/k	o of lig	and <sup>.</sup> ligand <sup>.</sup> F	

<sup>*a*</sup>Groups of five mice were injected intraperitoneally with <sup>152</sup>Eu-ligand complexes; 5 µmol/kg of ligand; ligand:Eu molar <sup>20</sup> ratio > 20; mice were euthanized at 24 h. Data, expressed as percent of injected <sup>152</sup>Eu (%, mean ± SD), were normalized to 100% material recovery for each five-mouse group. Discrepancies are due to rounding. SD =  $[\Sigma \text{ dev}^2 (n-1)^{-1}]^{1/2}$ ; for tissues, n = number of mice.

<sup>b</sup>Excreta of each five-mouse group were pooled; no SD is available.

25